Table 2 Use of palivizumab and resources saving during 2008-2009 campaign
From: Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing
| Â | Theoretical single use | Real use with vial sharing | Saving |
|---|---|---|---|
50 mg vials | 67 | 16 | 51 |
100 mg vials | 58 | 60 | -2 |
mg wasted | 3.176,88 | 777,08 | 2.399,80 |
Value | 80.087,09€ | 56.706,92€ | 23.380,17€ |